Skip to content

Evaluation of the efficacy of Berberine instead of clarithromycin against Helicobacter pylori in children, in vitro and in vivo

Evaluation of the efficacy of Berberine instead of clarithromycin against Helicobacter pylori in children, in vitro and in vivo

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17013319
Enrollment
Unknown
Registered
2017-11-09
Start date
2017-11-01
Completion date
Unknown
Last updated
2017-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

group A:losec-clarithromycin-amoxicillin therapy of 10-day
group A:losec-clarithromycin-amoxicillin therapy of 14-day
group C:losec-berberine-amoxicillin therapy of 10-day
group D:losec-berberine-amoxicillin therapy of 14-day

Sponsors

Guangzhou Wemen and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. No antibiotics, PPI, H2 receptor antagonists, NASAIDs and other drugs within one month before endoscopy; 2. No allergies to the drug used in the study; 3. No acute gastrointestinal bleeding obstruction; Circulation, respiratory, urinary, neurological, blood system diseases, no endocrine, genetic metabolism and other systemic diseases; 4. Endoscopic diagnosis of chronic superficial gastritis; 5. meet the diagnostic criteria for Hp infection.

Exclusion criteria

Exclusion criteria: 1. poor follow up; 2. gastrointestinal ulcers and bleeding; 3. can not tolerate adverse reactions; 4. other diseases happen during the treatment; 5. G6PD dificient.

Design outcomes

Primary

MeasureTime frame
eradication rate;

Secondary

MeasureTime frame
GI symtom;cost;

Countries

China

Contacts

Public ContactZhaohui Xu

Guangzhou Wemen and Children's Medical Center

xuer_hui@126.com+86 13660366402

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026